We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response

By LabMedica International staff writers
Posted on 29 May 2026

Tuberculosis (TB) remains the world’s leading infectious killer, with 10. More...

8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring gaps in understanding the host factors that determine protection versus progression. Clinical tools are needed to distinguish controlled infection from active disease and track treatment response. New findings now show that a metabolic biomarker in immune cells may help explain differential control of TB infection.

Trinity College Dublin researchers have identified an immune “energy signature” in circulating monocytes that differentiates latent TB infection from active disease. The signature reflects how these innate immune cells generate and use energy during host defense. The work centers on immunometabolism and links cellular energy pathways with antibacterial responsiveness.

In individuals with latent TB, monocytes remained metabolically flexible, a state associated with robust antibacterial activity. By contrast, monocytes from people with active TB showed impaired metabolism and weaker responses to infection. These functional differences indicate that immune-cell energy programs influence whether infection is contained or progresses.

The study, published in the Journal of Infection, focused on circulating monocytes and used single-cell metabolic profiling to compare latent infection with active disease. Investigators also observed that TB treatment could partially restore features of healthier immune-cell metabolism. These metabolic shifts may serve as correlates of protection and potential biomarkers of treatment response or disease recovery.

The work builds on growing international research into immunometabolism and provides one of the clearest comparisons to date between latent and active TB using single-cell metabolic profiling. By tying energy utilization to antibacterial readiness, the analysis outlines a measurable biological pattern linked to disease control. The authors note that the findings could help pave the way for improved TB monitoring tools.

“We found that the way immune cells generate and use energy appears to play an important role in determining whether TB remains controlled or progresses to active disease. In people with latent TB, these immune cells appear metabolically adaptable and ready to respond to infection. In active TB disease, however, the same cells show signs of dysfunction and are less capable of mounting an effective immune response. Latent TB is often thought of as a dormant state, but our findings show the immune system is actively working to keep infection under control,” said Dr. Gráinne Jameson, postdoctoral researcher in immunology at Trinity Translational Medicine Institute.

Related Links
Trinity College Dublin 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Urine Analyzer
respons® UDS100
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: WashU Medicine researchers found that dozens of blood proteins shift during Alzheimer’s treatment and may help monitor the effects of the medication. (Image Credit: Matt Miller/WashU Medicine)

Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment

Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more

Molecular Diagnostics

view channel
Image: University of Florida scientists Hugh Fan, Ph.D., and John Lednicky, Ph.D., led the development of a cost-effective, accurate handheld device capable of simultaneously testing for seven different mosquito-borne viruses. (Image Credit: UF Health photo by Hannah Clark)

Portable Test Differentiates Seven Mosquito-Borne Viruses at Point of Care

Mosquito-borne viral illnesses can present with overlapping symptoms such as fever, joint pain, fatigue, and rash, making them difficult to distinguish without laboratory testing. In these settings, clinicians... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.